Share on StockTwits

Genomic Health (NASDAQ:GHDX)’s share price reached a new 52-week low on Monday , AnalystRatings.Net reports. The stock traded as low as $24.50 and last traded at $25.22, with a volume of 50,519 shares traded. The stock had previously closed at $24.68.

A number of analysts have recently weighed in on GHDX shares. Analysts at Zacks reiterated a “neutral” rating on shares of Genomic Health in a research note on Friday, April 4th. They now have a $27.00 price target on the stock. Separately, analysts at TheStreet downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Wednesday, March 5th. Finally, analysts at Credit Suisse downgraded shares of Genomic Health from an “outperform” rating to a “neutral” rating in a research note on Friday, February 7th. Five equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $31.40.

The stock’s 50-day moving average is $26.94 and its 200-day moving average is $29.64. The company’s market cap is $791.1 million.

Genomic Health (NASDAQ:GHDX) last released its earnings data on Tuesday, February 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.27. The company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $69.20 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. Analysts expect that Genomic Health will post $-0.85 EPS for the current fiscal year.

Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.